Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171049 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
A Phase 3 study, sponsored by Anthos Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
NCT05171049 is a Phase 3 study that was terminated before completion, run by Anthos Therapeutics. The registered enrollment target is 1,150 participants.
The verdict
NCT05171049, a Phase 3 study, was terminated before completion, sponsored by Anthos Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
Study Summary
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Interventions
- DRUG Apixaban
- BIOLOGICAL Abelacimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2026-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05171049
The ClinicalTrials.gov registry entry for NCT05171049 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthos Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT05171049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05171049 about?
NCT05171049 is a clinical study titled "A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE". This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
What is the current status of trial NCT05171049?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2022-05-05. Estimated completion is 2026-02-04.
What interventions are being tested in trial NCT05171049?
The interventions under investigation include: Apixaban (DRUG), Abelacimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05171049?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.